The Role of Microbiota on the Development of Lung Cancer
NCT ID: NCT03454685
Last Updated: 2019-06-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2018-01-30
2020-03-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Exploratory Study of the Microbiome of Upper Gastrointestinal in the Pathogenesis of Multiple Primary Lung Cancer
NCT06973499
Gut Microbiota and Cancer Immunotherapy Response
NCT04682327
Multiomics Tumor Evolution Model of NSCLC
NCT05352035
Microbiota and the Lung Cancer
NCT03068663
Survival Outcomes of Lung Cancer
NCT03647098
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NCSLC group
NSCLC patients,including stage I to stage IV.
without intervention type
Without intervention,this study is just an observational study.
Healthy subjects
healthy subjects
without intervention type
Without intervention,this study is just an observational study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
without intervention type
Without intervention,this study is just an observational study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xiaorong Dong
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xiaorong Dong
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
dong xiaorong, Dr
Role: STUDY_DIRECTOR
china government
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Union hospital
Wuhan, Hubei, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
dong xiaorong, Dr
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Lu H, Gao NL, Tong F, Wang J, Li H, Zhang R, Ma H, Yang N, Zhang Y, Wang Y, Liang Z, Zeng H, Chen WH, Dong X. Alterations of the Human Lung and Gut Microbiomes in Non-Small Cell Lung Carcinomas and Distant Metastasis. Microbiol Spectr. 2021 Dec 22;9(3):e0080221. doi: 10.1128/Spectrum.00802-21. Epub 2021 Nov 17.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
745435
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.